Gender Differences in the Level of Antibodies to Measles Virus in Adults

Individuals without a protective antibody level are susceptible to measles infection. There are differences in the persistence of antibodies after vaccination and infection, while the impact of gender on this process has not been sufficiently studied. Measles Ig G antibodies were measured in 1742 em...

Full description

Saved in:
Bibliographic Details
Published inVaccines (Basel) Vol. 9; no. 5; p. 494
Main Authors Kostinov, P. Mikhail, Zhuravlev, I. Pavel, Filatov, N. Nikolay, Kostinova, M. Аristitsa, Polishchuk, B. Valentina, Shmitko, D. Anna, Mashilov, V. Cyrill, Vlasenko, E. Anna, Ryzhov, A. Alexey, Kostinov, M. Аnton
Format Journal Article
LanguageEnglish
Published Basel MDPI AG 12.05.2021
MDPI
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Individuals without a protective antibody level are susceptible to measles infection. There are differences in the persistence of antibodies after vaccination and infection, while the impact of gender on this process has not been sufficiently studied. Measles Ig G antibodies were measured in 1742 employees of a large hospital facility—403 men and 1339 women aged from 25 to 67 years; 15% participants had antibody levels less than the protective threshold of ≥0.18 IU/mL. Significant differences were found in the age group 40–49, where the level of IgG antibodies to measles among men was higher than among women (1.51 IU/mL (0.41; 3.38) vs. 0.70 IU/mL (0.22;1.98) respectively, (U = 3.2, p = 0,001)); in the age group 60 and older, by contrast, the level of antibodies among women was higher compared to men (3.29 IU/mL (1.72; 4.07) vs. 2.90 IU/mL (1.46; 3.53) respectively (U = 2.2, p = 0.03)). The proportion of seronegative women in the age group 40–49 was significantly higher than of seronegative men: 22 [18–26]% and 11 [6–18]% respectively (χ2 = 7.0, p = 0.001). The revealed gender characteristics that affect persistence of measles immunity may be important in personalization of vaccinal prevention for men and women.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2076-393X
2076-393X
DOI:10.3390/vaccines9050494